Aim and Objective: This study aims to assess the efficacy of a new electromotive system for the transcutaneous delivery of verapamil or of hyaluronic acid to improve the symptoms of Peyronie's disease (PD) in patients with a curvature deformity of <30° at the beginning of therapy. Methods and Materials: A total of 61 PD patients were studied. 30 were randomly assigned to receive verapamil 10 mg/session (Isoptin®, BGP Products, Rome-Italy) (Group 1, median age 56 years, range 49-62), and 31 were randomly assigned to receive hyaluronic acid 8 mg/session (Sinovial®, IBSA, Lodi-Italy) (Group 2, median age 58 years, range 51-56). There were 10 sessions, 2 sessions/week for each drug. Each drug was transdermally administered using the hydroelectrophoresis technique and carried out using a Hydro4 and apparatus (Swiss4Med SA, Morbio Inferiore, Switzerland). With respect to the efficacy of the drugs studied, the end points were side effects, pain, erectile function, penile deviations and plaque area (cm 2 ) before, and 3 and 6 months after drug administration. The differences were assessed using the Mann-Whitney rank test (unmatched groups) or using the Wilcoxon signed-rank test (matched groups). The differences between the groups in terms of side effects were assessed using the Chi-square test. Results: No significant difference emerged among the baseline values of the two groups. Pain, erectile function, plaque area, and penile deformity significantly improved in both groups after treatment, but a notably higher improvement occurred in the patients in whom hyaluronic acid was administered. Only a few negligible side effects occurred in the Group 1 patients treated with verapamil, with no significant difference between the groups. Conclusion: Administration of both hyaluronic acid and verapamil using the Hydro4 and apparatus is a safe and efficient method for PD therapy.